American Association for Cancer Research
mct-22-0723_figure_s2_suppsf2.pdf (221.78 kB)

Figure S2 from Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103

Download (221.78 kB)
journal contribution
posted on 2023-06-01, 08:21 authored by Ryan T. Bushey, Ruchi Saxena, Michael J. Campa, Elizabeth B. Gottlin, You-Wen He, Edward F. Patz

Deposition of intratumoral C3dg and C3d.


U.S. Department of Defense (US)



Development of novel therapeutic antibodies that not only kill tumor cells but modulate the adaptive immune response has the potential to produce long term anticancer immunity and a durable clinical response. We previously reported the discovery of anti-complement factor H (CFH) autoantibodies in patients with lung cancer that were associated with early-stage disease and exceptional outcomes. The human mAb GT103, produced from a single CFH autoantibody-expressing B cell of a patient with lung cancer, recognizes a conformationally distinct epitope on tumor cells, kills tumor cells, and inhibits tumor growth in animal studies. Recent experiments have shown that GT103 restructures the tumor microenvironment and initiates a robust antitumoral adaptive immune response. The current study further elucidates several mechanisms by which GT103 kills tumor cells and drives the immune program. Here we show GT103 has specificity for tumor cells without binding to native soluble CFH or normal tissues. GT103 causes complement C3 split product deposition on tumor cells in vitro and in vivo, triggers antibody-dependent cellular phagocytosis, and increases translocation of the danger-associated molecular pattern molecule calreticulin to the plasma membrane. We also demonstrate that GT103 causes B-cell activation in vitro and in vivo, and that GT103 antitumor activity in vivo is B-cell dependent. The complex mechanism of GT103, a tumor-specific antibody that kills tumor cells and stimulates an immune response, supports further development of this human-derived antibody as a novel therapeutic option for patients with lung cancer.

Usage metrics

    Molecular Cancer Therapeutics